A systematic review of published clinical trials in the systemic treatment of adrenocortical carcinoma: An initiative led on behalf of the Global Society of Rare Genitourinary Tumors
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A systematic review of published clinical trials in the systemic treatment of adrenocortical carcinoma: An initiative led on behalf of the Global Society of Rare Genitourinary Tumors
Authors
Keywords
-
Journal
Clinical Genitourinary Cancer
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-10-24
DOI
10.1016/j.clgc.2022.10.011
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Point-of-Care Resource to Improve Care of Patients with Adrenal Mass: www.AdrenalMass.org
- (2022) Marshall Strother et al. EUROPEAN UROLOGY
- First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study.
- (2022) Alfredo Berruti et al. JOURNAL OF CLINICAL ONCOLOGY
- Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma
- (2022) Bassel Nazha et al. ONCOLOGIST
- Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma
- (2022) M. Laganà et al. ESMO Open
- EO2401, a novel microbiome-derived therapeutic vaccine for patients with adrenocortical carcinoma (ACC): Preliminary results of the SPENCER study.
- (2022) Eric Baudin et al. JOURNAL OF CLINICAL ONCOLOGY
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
- (2021) Matthew J Page et al. BMJ-British Medical Journal
- Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
- (2021) Manisha H. Shah et al. Journal of the National Comprehensive Cancer Network
- A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma
- (2020) David C. Smith et al. INVESTIGATIONAL NEW DRUGS
- Nivolumab in metastatic adrenocortical carcinoma: results of a phase II trial
- (2019) Benedito A Carneiro et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma
- (2019) Mouhammed Amir Habra et al. Journal for ImmunoTherapy of Cancer
- PD-1 Blockade in Advanced Adrenocortical Carcinoma
- (2019) Nitya Raj et al. JOURNAL OF CLINICAL ONCOLOGY
- Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis
- (2018) Yongquan Tang et al. Biomed Research International
- European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors
- (2018) Martin Fassnacht et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial
- (2018) Christophe Le Tourneau et al. Journal for ImmunoTherapy of Cancer
- Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma
- (2016) Siyuan Zheng et al. CANCER CELL
- Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study
- (2015) Martin Fassnacht et al. LANCET ONCOLOGY
- Adrenocortical Carcinoma
- (2014) Tobias Else et al. ENDOCRINE REVIEWS
- Integrated genomic characterization of adrenocortical carcinoma
- (2014) Guillaume Assié et al. NATURE GENETICS
- Borderline Resectable Adrenal Cortical Carcinoma: A Potential Role for Preoperative Chemotherapy
- (2014) Brian K. Bednarski et al. WORLD JOURNAL OF SURGERY
- The Combination of Insulin-Like Growth Factor Receptor 1 (IGF1R) Antibody Cixutumumab and Mitotane as a First-Line Therapy for Patients with Recurrent/Metastatic Adrenocortical Carcinoma: a Multi-institutional NCI-Sponsored Trial
- (2014) Antonio M. Lerario et al. Hormones & Cancer
- Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study
- (2013) T Urup et al. BRITISH JOURNAL OF CANCER
- Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma
- (2013) A Naing et al. BRITISH JOURNAL OF CANCER
- Sunitinib in Refractory Adrenocortical Carcinoma: A Phase II, Single-Arm, Open-Label Trial
- (2012) Matthias Kroiss et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Combination Chemotherapy in Advanced Adrenocortical Carcinoma
- (2012) Martin Fassnacht et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma
- (2011) Alfredo Berruti et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study
- (2010) Paola Sperone et al. ENDOCRINE-RELATED CANCER
- Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma
- (2009) Paul Haluska et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Adrenocortical carcinoma in the United States
- (2008) Karl Y. Bilimoria et al. CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now